In a decisive move toward selfsufficiency, the U.S. Food and Drug Administration (FDA) has launched the FDA PreCheck initiative, unveiled on August 7, 2025. This program is designed to reinforce the domestic pharmaceutical supply chain by
simplifying regulatory processes, accelerating facility development, and ultimately ensuring that critical medicines remain available to American patients without interruption.
PreCheck is built around
two core phases:
Facility Readiness Phase – Manufacturers can engage early with the FDA to discuss facility design, construction plans, and quality systems before beginning production. They may submit details, such as layouts and Quality Management Maturity
(QMM) practices, through Type V Drug Master Files, enabling faster readiness assessments. Application Submission Phase, Companies can receive early feedback on the Chemistry, Manufacturing, and Controls (CMC) portion of their applications,
reducing last-minute surprises and streamlining approval timelines.
FDA Commissioner Marty Makary has framed PreCheck as a key step in reducing U.S. dependence on overseas drug production. By encouraging early collaboration, the FDA aims to eliminate bottlenecks and create a stronger, more resilient
domestic manufacturing base. A public meeting is scheduled for September 30, where industry stakeholders will be invited to provide input and refine the program’s rollout.
The initiative follows President Trump’s executive order earlier this year, which directed federal agencies to cut unnecessary barriers for domestic drug makers. The order focused on streamlining review processes, removing duplicative
requirements, and tightening oversight of foreign manufacturing facilities to ensure consistent product quality. Pharmaceutical giants are already responding. Eli Lilly has announced a $27 billion investment in four new U.S. manufacturing
sites, projected to create over 3,000 high-skill jobs and nearly 10,000 construction roles. AstraZeneca has committed $50 billion by 2030 for U.S.-based manufacturing and research, including a major new facility dedicated to weight
management and metabolic disease treatments.
and ensures that patients can access life-saving medicines without delay. Together, the FDA’s PreCheck program, executive- level policy support, and large-scale corporate investment represent a pivotal shift toward innovation, security, and
resilience in American pharmaceutical production. The message is clear: the U.S. is not just aiming to make more medicines, it’s aiming to make them better, faster, and at home.
Add Comment